STUDY OBJECTIVE: To determine the procedural feasibility of a pharmacist-led interdisciplinary service for providing genotype-guided warfarin dosing for hospitalized patients newly starting warfarin. DESIGN: Prospective observational study. SETTING: A 438-bed tertiary care hospital affiliated with a large academic institution. PATIENTS: Eighty patients who started warfarin therapy and were managed by a newly implemented pharmacogenetics service. INTERVENTION: All patients received routine warfarin genotyping and clinical pharmacogenetics consultation. MEASUREMENTS AND MAIN RESULTS: The primary outcomes were percentage of genotype-guided dose recommendations available prior to the second warfarin dose and adherence of the medical staff to doses recommended by the pharmacogenetics service. Of 436 genotype orders placed during the first 6 months of the service, 190 (44%) were deemed appropriate. For the 80 patients on the service who consented to data collection, 76% of the genotypes were available prior to the second warfarin dose. The median (range) time from genotype order to genotype result was 26 hours (7-80 hrs), and the time to genotype-guided dose recommendation was 30 hours (7-80 hrs). A total of 73% of warfarin doses ordered by the medical staff were within 0.5 mg of the daily dose recommended by the pharmacogenetics consult service. CONCLUSION: Providing routine genotype-guided warfarin dosing supported by a pharmacogenetics consult service is feasible from a procedural standpoint, with most genotypes available prior to the second warfarin dose and good adherence to genotype-guided dose recommendations by the medical staff.
STUDY OBJECTIVE: To determine the procedural feasibility of a pharmacist-led interdisciplinary service for providing genotype-guided warfarin dosing for hospitalized patients newly starting warfarin. DESIGN: Prospective observational study. SETTING: A 438-bed tertiary care hospital affiliated with a large academic institution. PATIENTS: Eighty patients who started warfarin therapy and were managed by a newly implemented pharmacogenetics service. INTERVENTION: All patients received routine warfarin genotyping and clinical pharmacogenetics consultation. MEASUREMENTS AND MAIN RESULTS: The primary outcomes were percentage of genotype-guided dose recommendations available prior to the second warfarin dose and adherence of the medical staff to doses recommended by the pharmacogenetics service. Of 436 genotype orders placed during the first 6 months of the service, 190 (44%) were deemed appropriate. For the 80 patients on the service who consented to data collection, 76% of the genotypes were available prior to the second warfarin dose. The median (range) time from genotype order to genotype result was 26 hours (7-80 hrs), and the time to genotype-guided dose recommendation was 30 hours (7-80 hrs). A total of 73% of warfarin doses ordered by the medical staff were within 0.5 mg of the daily dose recommended by the pharmacogenetics consult service. CONCLUSION: Providing routine genotype-guided warfarin dosing supported by a pharmacogenetics consult service is feasible from a procedural standpoint, with most genotypes available prior to the second warfarin dose and good adherence to genotype-guided dose recommendations by the medical staff.
Authors: Brian S Finkelman; Brian F Gage; Julie A Johnson; Colleen M Brensinger; Stephen E Kimmel Journal: J Am Coll Cardiol Date: 2011-02-01 Impact factor: 24.094
Authors: P Lenzini; M Wadelius; S Kimmel; J L Anderson; A L Jorgensen; M Pirmohamed; M D Caldwell; N Limdi; J K Burmester; M B Dowd; P Angchaisuksiri; A R Bass; J Chen; N Eriksson; A Rane; J D Lindh; J F Carlquist; B D Horne; G Grice; P E Milligan; C Eby; J Shin; H Kim; D Kurnik; C M Stein; G McMillin; R C Pendleton; R L Berg; P Deloukas; B F Gage Journal: Clin Pharmacol Ther Date: 2010-04-07 Impact factor: 6.875
Authors: Benjamin D Horne; Petra A Lenzini; Mia Wadelius; Andrea L Jorgensen; Stephen E Kimmel; Paul M Ridker; Niclas Eriksson; Jeffrey L Anderson; Munir Pirmohamed; Nita A Limdi; Robert C Pendleton; Gwendolyn A McMillin; James K Burmester; Daniel Kurnik; C Michael Stein; Michael D Caldwell; Charles S Eby; Anders Rane; Jonatan D Lindh; Jae-Gook Shin; Ho-Sook Kim; Pantep Angchaisuksiri; Robert J Glynn; Kathryn E Kronquist; John F Carlquist; Gloria R Grice; Robert L Barrack; Juan Li; Brian F Gage Journal: Thromb Haemost Date: 2011-12-21 Impact factor: 5.249
Authors: J A Johnson; L Gong; M Whirl-Carrillo; B F Gage; S A Scott; C M Stein; J L Anderson; S E Kimmel; M T M Lee; M Pirmohamed; M Wadelius; T E Klein; R B Altman Journal: Clin Pharmacol Ther Date: 2011-09-07 Impact factor: 6.875
Authors: Gregory M Cooper; Julie A Johnson; Taimour Y Langaee; Hua Feng; Ian B Stanaway; Ute I Schwarz; Marylyn D Ritchie; C Michael Stein; Dan M Roden; Joshua D Smith; David L Veenstra; Allan E Rettie; Mark J Rieder Journal: Blood Date: 2008-06-05 Impact factor: 22.113
Authors: B F Gage; C Eby; J A Johnson; E Deych; M J Rieder; P M Ridker; P E Milligan; G Grice; P Lenzini; A E Rettie; C L Aquilante; L Grosso; S Marsh; T Langaee; L E Farnett; D Voora; D L Veenstra; R J Glynn; A Barrett; H L McLeod Journal: Clin Pharmacol Ther Date: 2008-02-27 Impact factor: 6.875
Authors: T E Klein; R B Altman; N Eriksson; B F Gage; S E Kimmel; M-T M Lee; N A Limdi; D Page; D M Roden; M J Wagner; M D Caldwell; J A Johnson Journal: N Engl J Med Date: 2009-02-19 Impact factor: 91.245
Authors: P C Mathias; N Hendrix; W-J Wang; K Keyloun; M Khelifi; P Tarczy-Hornoch; B Devine Journal: Clin Pharmacol Ther Date: 2017-06-05 Impact factor: 6.875
Authors: Brittany L Melton; Alan J Zillich; Jason Saleem; Alissa L Russ; James E Tisdale; Brian R Overholser Journal: Appl Clin Inform Date: 2016-11-23 Impact factor: 2.342
Authors: Gary Tse; Mengqi Gong; Guangping Li; Sunny Hei Wong; William K K Wu; Wing Tak Wong; Leonardo Roever; Alex Pui Wai Lee; Gregory Y H Lip; Martin C S Wong; Tong Liu Journal: Br J Clin Pharmacol Date: 2018-06-21 Impact factor: 4.335
Authors: Katrina M Romagnoli; Richard D Boyce; Philip E Empey; Solomon Adams; Harry Hochheiser Journal: Int J Med Inform Date: 2015-11-30 Impact factor: 4.046
Authors: Larisa H Cavallari; Craig R Lee; Julio D Duarte; Edith A Nutescu; Kristin W Weitzel; George A Stouffer; Julie A Johnson Journal: Am J Health Syst Pharm Date: 2016-12-01 Impact factor: 2.637